市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Nuvalent, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 4.0 |
| 内部交易活动 | -2.5 |
| 价格波动 | -0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -2.0 |
| 平均 | 0.30 |
|
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company’s operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 2.85% |
| 机构持股比例 | 110.02% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Commodore Capital Lp | 30 Sep 2025 | 1,400,000 |
| Vestal Point Capital, Lp | 30 Sep 2025 | 1,100,000 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 158.00 (Baird, 55.22%) | 购买 |
| 中 | 140.00 (37.54%) | |
| 低 | 112.00 (Barclays, 10.03%) | 购买 |
| 平均值 | 140.18 (37.72%) | |
| 总计 | 11 购买 | |
| 平均价格@调整类型 | 104.16 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| JP Morgan | 19 Dec 2025 | 145.00 (42.45%) | 购买 | 103.80 |
| Truist Securities | 24 Nov 2025 | 140.00 (37.54%) | 购买 | 109.53 |
| Baird | 18 Nov 2025 | 158.00 (55.22%) | 购买 | 104.24 |
| Goldman Sachs | 18 Nov 2025 | 135.00 (32.63%) | 购买 | 104.24 |
| Guggenheim | 18 Nov 2025 | 155.00 (52.27%) | 购买 | 104.24 |
| HC Wainwright & Co. | 17 Nov 2025 | 155.00 (52.27%) | 购买 | 108.00 |
| Leerink Partners | 17 Nov 2025 | 149.00 (46.38%) | 购买 | 108.00 |
| Stifel | 17 Nov 2025 | 135.00 (32.63%) | 购买 | 108.00 |
| Canaccord Genuity | 12 Nov 2025 | 126.00 (23.78%) | 购买 | 97.03 |
| Barclays | 31 Oct 2025 | 112.00 (10.03%) | 购买 | 99.32 |
| UBS | 31 Oct 2025 | 132.00 (29.68%) | 购买 | 99.32 |
| 显示更多 | ||||
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| MILLER DEBORAH ANN | - | 110.52 | -15,000 | -1,677,785 |
| 累积净数量 | -15,000 | |||
| 累积净值 ($) | -1,677,785 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 110.52 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| MILLER DEBORAH ANN | 职员 | 22 Jan 2026 | 自动卖出 (-) | 14,300 | 111.99 | 1,601,457 |
| MILLER DEBORAH ANN | 职员 | 22 Jan 2026 | 执行期权 | 14,300 | - | - |
| MILLER DEBORAH ANN | 职员 | 21 Jan 2026 | 自动卖出 (-) | 700 | 109.04 | 76,328 |
| MILLER DEBORAH ANN | 职员 | 21 Jan 2026 | 执行期权 | 700 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合